Search research articles

关于 JoVE

概览领导团队博客 JoVE 帮助中心

作者

出版流程编辑委员会范围与政策同行评审常见问题投稿

图书馆员

用户评价订阅访问资源图书馆顾问委员会常见问题

研究

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments 存档

教育

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual 教师资源中心教师网站

使用条款与条件

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序

Same author

Precision Transfusion Medicine in the Omics Era.

Blood·2026

Same author

Genetic architecture of the murine serum metabolome reveals carboxyl esterases as master regulators of circulating fatty acid metabolism.

bioRxiv : the preprint server for biology·2026

Same author

Resolution of inflammation increases erythropoiesis.

Blood. Red cells & iron·2026

Same author

FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia.

Leukemia·2026

Same author

Exposure to perfluorooctanoic acid accelerates <i>Drosophila melanogaster</i> juvenile development and disrupts mitochondrial metabolism.

bioRxiv : the preprint server for biology·2026

Same author

Blood Cells Far from Equilibrium: Redox Adaptation in Health and Disease.

Antioxidants (Basel, Switzerland)·2026

Search research articles

相关实验视频

Updated: Jun 17, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

对生殖中心B细胞样扩散型大B细胞淋巴瘤的NAMPT抑制剂的重新使用

Claudio Scuoppo^1,2, Bowen Cai¹, Kenneth Ofori^1,2

¹Institute for Cancer Genetics, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York.

Blood cancer discovery

|August 6, 2024

概括

尼古丁胺胺酸基转移酶抑制剂 (NAMPTi) 显示出针对生殖中心B细胞样扩散大B细胞淋巴瘤 (GCB-DLBCL) 的子集的活性. NAMPT:PARP1比率预测了灵敏度,特别是在BCL2转移的GCB-DLBCL中.

更多相关视频

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

相关实验视频

Last Updated: Jun 17, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

扩散性大B细胞淋巴瘤 (DLBCL) 包括具有明显特征的活性B细胞样 (ABC) 和生殖中心B细胞样 (GCB) 亚型.
针对ABC-DLBCL存在向疗法,但对高风险GCB-DLBCL的有效治疗仍然有限.

研究的目的:

在DLBCL中选现有药物的亚型特定活性.
确定GCB-DLBCL的新型治疗策略,特别是那些具有BCL2转位的治疗策略.

主要方法:

对211种已批准或临床开发药物的DLBCL亚型的活性进行查.
生物化学和遗传救援方法验证尼古丁胺酸转移酶抑制剂 (NAMPTi).
分析NAMPT:PARP1RNA比率作为NAMPTi敏感性的预测生物标志物.

主要成果:

NAMPT 抑制剂在体外和体外GCB-DLBCL的一个子集中表现出活性.
鉴定出NAMPT:PARP1转录比率是DLBCL亚型中NAMPTi敏感性的预测指标.
当用NAMPTi治疗BCL2-转移的GCB-DLBCL时,观察到更高的抗瘤活性,在BCL2抑制方面观察到协同效应.

结论:

抑制NAMPT代表了对BCL2-转移的GCB-DLBCL的有前途的治疗策略.
BCL2转位可以作为生物标志物,用于识别可能受益于NAMPT抑制的患者.